GlassScriptPhysician profile
William T Fuller
NPI 1205323177
$10,269.78
in general payments reported to CMS, 2019-2025
30 companies · $6,111 in 2025
The $6,111 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.92 · 2021: $498 · 2022: $855 · 2023: $1,129 · 2024: $1,633 · 2025: $6,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,135 · Education: $2,500 · Travel and Lodging: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.76 |
| Education | $2,500.00 |
| Travel and Lodging | $1,237.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,834.24 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,000.47 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $934.19 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $721.81 | 2021-2023 | Uptravi |
| Mallinckrodt Hospital Products INC. | $566.25 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.31 | 2023-2025 | Ofev, Jascayd |
| Abbvie INC. | $501.46 | 2021-2025 | |
| Genzyme Corporation | $296.55 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $292.93 | 2021-2025 | Dupixent |
| Verona Pharma, INC. | $254.84 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $158.16 | 2022-2025 | Zerbaxa, Recarbrio |
| Electromed, INC. | $148.73 | 2024-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $137.11 | 2024-2025 | Glassia |
| Abiomed | $129.60 | 2024 | Impella |
| Insmed, INC. | $119.86 | 2022-2025 | Brinsupri, Arikayce |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $113.81 | 2022-2024 | |
| Pfizer INC. | $74.68 | 2019-2022 | |
| United Therapeutics Corporation | $70.81 | 2022-2025 | Tyvaso, Tyvaso |
| Inari Medical, INC. | $67.74 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ani Pharmaceuticals, INC. | $46.73 | 2024-2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $43.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $42.17 | 2024 | Xarelto |
| Mylan Specialty L.P. | $40.42 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $30.91 | 2019 | |
| Amgen INC. | $30.84 | 2025 | Tezspire |
| Viatris Specialty LLC | $27.13 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.01 | 2021 | |
| Novo Nordisk INC | $18.21 | 2021 | |
| Genentech USA, INC. | $17.96 | 2022 | |
| Avanos Medical | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.